scholarly journals A novel pyroptosis-related gene signature to predict outcomes in laryngeal squamous cell carcinoma

Aging ◽  
2021 ◽  
Author(s):  
Chongchang Zhou ◽  
Guowen Zhan ◽  
Yangli Jin ◽  
Jianneng Chen ◽  
Zhisen Shen ◽  
...  
BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Guichuan Huang ◽  
Jing Zhang ◽  
Ling Gong ◽  
Yi Huang ◽  
Daishun Liu

Abstract Background Lung cancer is one of the most lethal and most prevalent malignant tumors worldwide, and lung squamous cell carcinoma (LUSC) is one of the major histological subtypes. Although numerous biomarkers have been found to be associated with prognosis in LUSC, the prediction effect of a single gene biomarker is insufficient, especially for glycolysis-related genes. Therefore, we aimed to develop a novel glycolysis-related gene signature to predict survival in patients with LUSC. Methods The mRNA expression files and LUSC clinical information were obtained from The Cancer Genome Atlas (TCGA) dataset. Results Based on Gene Set Enrichment Analysis (GSEA), we found 5 glycolysis-related gene sets that were significantly enriched in LUSC tissues. Univariate and multivariate Cox proportional regression models were performed to choose prognostic-related gene signatures. Based on a Cox proportional regression model, a risk score for a three-gene signature (HKDC1, ALDH7A1, and MDH1) was established to divide patients into high-risk and low-risk subgroups. Multivariate Cox regression analysis indicated that the risk score for this three-gene signature can be used as an independent prognostic indicator in LUSC. Additionally, based on the cBioPortal database, the rate of genomic alterations in the HKDC1, ALDH7A1, and MDH1 genes were 1.9, 1.1, and 5% in LUSC patients, respectively. Conclusion A glycolysis-based three-gene signature could serve as a novel biomarker in predicting the prognosis of patients with LUSC and it also provides additional gene targets that can be used to cure LUSC patients.


2021 ◽  
Vol 8 ◽  
Author(s):  
Jiahang Song ◽  
Yanhu Liu ◽  
Xiang Guan ◽  
Xun Zhang ◽  
Wenda Yu ◽  
...  

Esophageal squamous cell carcinoma (ESCC) accounts for the main esophageal cancer (ESCA) type, which is also associated with the greatest malignant grade and low survival rates worldwide. Ferroptosis is recently discovered as a kind of programmed cell death, which is indicated in various reports to be involved in the regulation of tumor biological behaviors. This work focused on the comprehensive evaluation of the association between ferroptosis-related gene (FRG) expression profiles and prognosis in ESCC patients based on The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). ALOX12, ALOX12B, ANGPTL7, DRD4, MAPK9, SLC38A1, and ZNF419 were selected to develop a novel ferroptosis-related gene signature for GEO and TCGA cohorts. The prognostic risk model exactly classified patients who had diverse survival outcomes. In addition, this study identified the ferroptosis-related signature as a factor to independently predict the risk of ESCC. Thereafter, we also constructed the prognosis nomogram by incorporating clinical factors and risk score, and the calibration plots illustrated good prognostic performance. Moreover, the association of the risk score with immune checkpoints was observed. Collectively, the proposed ferroptosis-related gene signature in our study is effective and has a potential clinical application to predict the prognosis of ESCC.


2021 ◽  
Author(s):  
Haimei Qin ◽  
Junli Wang ◽  
Biyun Liao ◽  
Zhonglin Liu ◽  
Rong Wang

Abstract Background: Head and neck squamous cell carcinoma (HNSCC) is most diagnosed at an advanced stage with poor prognosis. Single gene biomarkers cannot have enough predictive ability in HNSCC. Glycolysis participating in cancers was verified. Thus, this study aimed to identify glycolysis-related gene signature predict the outcome of HNSCC. Methods: The mRNA expression data of HNSCC downloaded The Cancer Genome Atlas (TCGA) project was analyzed by Gene Set Enrichment Analysis (GSEA). We use the Cox proportional regression model to construct a prognostic model. Kaplan–Meier and receiver operating characteristic (ROC) curves were employed to estimate the signature. We also analyzed the relationship of the signature and cancer subtypes. Results: We identified nine glycolysis-related genes including G6PD, EGFR, ALDH2, GPR87, STC2, PDK3, ELF3, STC1 and GNPDA1 as prognosis-related genes signature in HNSCC. HNSCC patients were divided into high and low risk group according to the signature. High risk group showed more poor prognosis and the risk score can precisely predict the prognosis of HNSCC. Additionally, the signature also can be used in cancer subtypes. Conclusion: This study established the 9-mRNA glycolysis signature which may serve as a prospective biomarker for prognosis and novel treatment target in HNSCC.


2021 ◽  
Vol 11 ◽  
Author(s):  
Cailian Wang ◽  
Xuyu Gu ◽  
Xiuxiu Zhang ◽  
Min Zhou ◽  
Yan Chen

BackgroundLung squamous cell carcinoma (LUSC) generally correlates with poor clinical prognoses due to the lack of available prognostic biomarkers. This study is designed to identify a potential biomarker significant for the prognosis and treatment of LUSC, so as to provide a scientific basis for clinical treatment decisions.MethodsGenomic changes in LUSC samples before and after radiation were firstly discussed to identify E2 factor (E2F) pathway of prognostic significance. A series of bioinformatics analyses and statistical methods were combined to construct a robust E2F-related prognostic gene signature. Furthermore, a decision tree and a nomogram were established according to the gene signature and multiple clinicopathological characteristics to improve risk stratification and quantify risk assessment for individual patients.ResultsIn our investigated cohorts, the E2F-related gene signature we identified was capable of predicting clinical outcomes and therapeutic responses in LUSC patients, besides, discriminative to identify high-risk patients. Survival analysis suggested that the gene signature was independently prognostic for adverse overall survival of LUSC patients. The decision tree identified the strong discriminative performance of the gene signature in risk stractification for overall survival while the nomogram demonstrated a high accuracy.ConclusionThe E2F-related gene signature may help distinguish high-risk patients so as to formulate personalized treatment strategy in LUSC patients.


2021 ◽  
Author(s):  
Weiwen Zhu ◽  
Jiayi Zhang ◽  
Mengyao Wang ◽  
Rundong Zhai ◽  
Yanbin Xu ◽  
...  

Abstract Objective: Head and neck squamous cell carcinoma (HNSCC) is a major threat to public health. Pyroptosis is a form of inflammatory programmed cell death that is still incompletely understood. The role of pyroptotic cell death in HNSCC remains to be fully defined. As such, the present study was developed to explore the potential prognostic utility of a pyroptosis-related gene (PRG) signature in HNSCC.Methods: PRG expression patterns and the associated mutational landscape in HNSCC were analyzed, after which a 6-gene prognostic model was constructed through least absolute shrinkage and selection operator (LASSO) and Cox regression analyses using the TCGA dataset, followed by validation with two GEO datasets (GSE41643 and GSE65858). Potential predictors of patient outcomes associated with this 6-gene model were identified through topological degree analyses of a protein-protein interaction network. Lastly, the prognostic value of NLRP3 as a predictor of HNSCC patient prognosis was established through immunohistochemical (IHC) analyses of samples from 176 HNSCC patients.Results: Differentially expressed PRGs were able to readily differentiate between HNSCC tumors and normal tissues. Risk scores derived from the 6-gene PRG model were independent predictors of HNSCC patient prognosis, and genes that were differentially expressed between low- and high-risk groups were associated with tumor immunity. IHC analyses further supported the value of NLRP3 as a predictor of HNSCC patient outcomes. Conclusions: Overall, these results highlight a novel prognostic gene signature that offers value in the context of HNSCC patient evaluation, although additional research will be essential to elucidate the mechanisms linking these PRGs to HNSCC outcomes.


Sign in / Sign up

Export Citation Format

Share Document